Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin transporters.

Takeshi Inoue1, Ichiro Kusumi, Mitsuhiro Yoshioka

  • 1Department of Psychiatry, Hokkaido University, Graduate School of Medicine, Sapporo, Japan.

Current Drug Targets. CNS and Neurological Disorders
|May 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using multi-trait polygenic scores to predict lithium responsiveness in patients with bipolar disorder.

medRxiv : the preprint server for health sciences·2026
Same author

Association between higher cerebrospinal fluid levels of phosphorylated tau and reduced depressive symptoms in patients with cognitive decline.

PCN reports : psychiatry and clinical neurosciences·2025
Same author

Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder.

Biological psychiatry global open science·2025
Same author

Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey.

Schizophrenia research. Cognition·2025
Same author

Pathway-Specific Polygenic Scores for Lithium Response for Predicting Clinical Lithium Treatment Response in Patients with Bipolar Disorder.

medRxiv : the preprint server for health sciences·2025
Same author

Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study.

Progress in neuro-psychopharmacology & biological psychiatry·2024
Same journal

Partial QSAR analysis of some selected natural inhibitors of FAAH suggests a working hypothesis for the development of endocannabinoid-based drugs.

Current drug targets. CNS and neurological disorders·2005
Same journal

Therapeutic perspectives of inhibitors of endocannabinoid degradation.

Current drug targets. CNS and neurological disorders·2005
Same journal

Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors.

Current drug targets. CNS and neurological disorders·2005
Same journal

Cannabinoids: between neuroprotection and neurotoxicity.

Current drug targets. CNS and neurological disorders·2005
Same journal

From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.

Current drug targets. CNS and neurological disorders·2005
Same journal

Endocannabinoids in neuroimmunology and stress.

Current drug targets. CNS and neurological disorders·2005
See all related articles

The serotonin transporter is a key target for antidepressants and neuropsychiatric disorder treatments. Genetic variations in this transporter may lead to new therapeutic strategies with improved side effect profiles.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • The serotonin transporter (SERT) is the primary target of selective serotonin reuptake inhibitors (SSRIs).
  • SSRIs are widely used for treating depression and various neuropsychiatric disorders.
  • A functional polymorphism in the SERT gene promoter has been identified, prompting research into its role in disorders.

Purpose of the Study:

  • To review recent studies on serotonin transporter (SERT) gene polymorphisms.
  • To explore the potential for developing novel therapeutic agents targeting SERT.
  • To define concepts related to SERT research that require further comprehensive review.

Main Methods:

  • Review of existing literature on serotonin transporter (SERT) gene functional polymorphism.

Related Experiment Videos

  • Analysis of studies investigating the association between SERT polymorphism and neuropsychiatric disorders.
  • Synthesis of current understanding regarding SERT as a drug target.

    • Main Results:

    • The serotonin transporter (SERT) gene polymorphism is linked to various neuropsychiatric conditions.
    • This genetic variation influences the efficacy and side effect profiles of SSRIs.
    • Emerging evidence suggests SERT could be a target for new classes of therapeutic agents.

    Conclusions:

    • The serotonin transporter (SERT) and its genetic variations offer promising avenues for novel neuropsychiatric treatments.
    • Further research into SERT modulation could lead to drugs with distinct therapeutic and safety profiles.
    • Understanding SERT genetics is crucial for personalized medicine approaches in psychiatry.